<DOC>
	<DOCNO>NCT01464827</DOCNO>
	<brief_summary>This study combination direct-acting antiviral agent ( DAA ) without ribavirin ( RBV ) patient chronic Hepatitis C Virus ( HCV ) .</brief_summary>
	<brief_title>ABT-450 With Ritonavir ABT-267 and/or ABT-333 With Without Ribavirin Genotype 1 Hepatitis C Virus Infected Patients</brief_title>
	<detailed_description>A study evaluate safety effectiveness experimental drug ABT-450 , ABT-267 ( also know ombitasvir ) , ABT-333 ( also know dasabuvir ) , ritonavir , ribavirin participant HCV . The study test safety effect combination drug treatment 24 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Males female 1870 year old , inclusive Females must postmenopausal 2 year surgically sterile practice specific form birth control Chronic hepatitis C virus ( HCV ) , genotype 1 infection Treatmentnaive OR nullresponders previous treatment pegylated interferon ( pegIFN ) ribavirin ( least 12 week treatment failure achieve 2 log10 HCV RNA decrease Week 12 ) No evidence liver cirrhosis Significant liver disease cause HCV primary cause Positive hepatitis B surface antigen antihuman immunodeficiency virus antibody Positive screen drug alcohol Significant sensitivity drug Use contraindicate prohibited medication within 1 month dose Abnormal laboratory test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>HCV</keyword>
	<keyword>Chronic Hepatitis C</keyword>
</DOC>